About Us
Sachdev Sidhu - Co-Founder
Sachdev Sidhu is a pioneer in protein engineering, inventor, and serial entrepreneur with 30 years of research/scientific experience. He obtained his PhD from Simon Fraser University in Canada and did postdoctoral studies in the Department of Protein Engineering at Genentech, where he then lead an independent research group from 1998-2008. In 2008 he returned to academics as a professor at the University of Toronto and is currently a professor and entrepreneur in residence at the University of Waterloo.
Dr. Sidhu is a co-founder of multiple companies in Canada, the USA, and India, including EPOK Therapeutics (2022), Aarvik Therapeutics (2021), Antlera Therapeutics (2019), Pionyr Immunhotherapeutics (2015), Northern Biologics (2014), and Dextera Biosciences (2008). He has engineered thousands of antibodies targeting hundreds of therapeutic targets and has developed alternative binding scaffolds including SH2 superbinders. Dr. Sidhu has co-authored over 300 scientific publications, and he is a co-inventor on close to 100 patents that have been granted or filed.
Dr. Robert Moritz - Co-Founder
Dr. Robert Moritz is a globally recognized leader in proteomics and analytical technology development. With over 40 years of experience, he has pioneered advanced methods for protein analysis, including post-translational modification detection, biomarker discovery, and high-throughput drug screening. His innovations have directly supported the creation of robust, scalable reagent and assay platforms used in research and diagnostics.
Dr. Moritz has authored over 330 peer-reviewed publications and holds multiple patents in proteomics technologies. He has held leadership roles in international scientific organizations, including Chair of the Human Proteome Project and Vice President of HUPO, and serves on several editorial and scientific advisory boards. As a founder of several life science companies, he brings deep technical expertise and industry insight to driving reagent innovation and customer-focused solutions.
Martin Verhoef - CEO
Martin Verhoef has over 35 years of experience in the life sciences and molecular diagnostics markets working in The Netherlands, Sweden, Germany and the U.S.. His work in Fortune 500 companies, as well as startups, gives Martin an exceptional view on starting and growing companies.
Currently, Chairman of OMAPiX, a spatial biology company and fractional CEO of Axoiya, a General Inception portfolio company. While at Inscopix, Martin was the Chief Commercial Officer and played a key role in the sale of the company to Bruker, Inc. Martin held VP positions in Marketing, Strategy and R&D at Molecular Devices, a Danaher operating company, before being promoted to VP of Innovation for the multibillion-dollar Life Sciences Instrumentation Group. At Ciphergen, a proteomics company, Verhoef was Executive Vice President and President of the tools business and participated in the IPO. At PrimeraDx, Martin was CEO and raised a total of $48M in Series A and B. He began his career at Agilent (then still Hewlett-Packard) as Marketing Manager and R&D Leader for the DNA micro-array program.
Martin holds a double BS degree in Clinical and Analytical Chemistry from the van‘t Hoff Institute in Rotterdam, The Netherlands.
Board seats:
GenNext Technologies: Director of the Board
IXRF Systems: Executive Director of the Board
OMAPix: Chairman of the Board